DUBLIN, Calif., Oct. 23 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today presented data on MP-470, its lead product candidate, and four additional posters, at the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics" in Geneva, Switzerland. MP-470, an orally bio-available multi-targeted tyrosine kinase inhibitor, showed encouraging tumor regression results in the first two arms (paclitaxel/carboplatin and carboplatin/etoposide) of its current Phase 1b clinical trial examining MP-470 combined with five standard of care (SOC) anticancer treatments.
"We are extremely pleased to report a series of important clinical and scientific advances achieved by our Company," said James S. Manuso, Ph.D., SuperGen's President and Chief Executive Officer. "In addition to MP-470's progress in the clinic, before year-end, we expect to enter SGI-1776, our PIM kinase inhibitor, into Phase 1 clinical trials. This will be our second novel drug in clinical development."
In a poster presentation (Abstract #403) entitled, "Clinical responses
of highly refractory solid tumor patients to oral MP-470, a multi-targeted
tyrosine kinase inhibitor, in combination with standard of care
chemotherapy regimens. Preliminary report from a multi-institutional phase
1b clinical trial," Dr. A. Tolcher, Director of Clinical Research at START
(South Texas Accelerated Research Therapeutics) in San Antonio, Texas,
highlighted data showing tumor regression in four patients in the two arms,
indicating that MP-470 may sensitize/re-sensitize tumors to the anticancer
effects of SOC regimens of DNA-damaging agents. Of note, MP-470 did not
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved